Drugs / CVL-562
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04457310 | Mar 2021 → Mar 2024 | schizophrenia | Yale University | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CVL-562 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04457310 ↗ |
| Known as | PF-06412562 | “This study will test whether CVL-562 (PF-06412562), a dopamine 1 partial agonist novel compound, affects working memory neural circuits in patients with early episode schizophrenia.” NCT04457310 ↗ |
| Action | Activate | “a dopamine 1 partial agonist” NCT04457310 ↗ |
| Route | Oral | “they will receive oral administration of specified doses of CVL-562 (PF-06412562)” NCT04457310 ↗ |